Allianz Asset Management
CALA

Allianz Asset Management’s Calithera Biosciences, Inc CALA Stock Holding History

Allianz Asset Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,098
Closed -$516K – 2745
2018
Q1 		$516K Buy
4,098
+117
+3% +$18.2K ﹤0.01% 2375
2017
Q4 		$665K Buy
+3,981
New +$1.02M ﹤0.01% 2348

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Allianz Asset Management's CALA Position: Q2 2018 in Review

Allianz Asset Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2018, closing a stake of 4,098 shares — an estimated $516K sold.

Allianz Asset Management first reported a position in CALA in Q4 2017 and held it in 2 quarters. The position peaked at $665K in Q4 2017. 90 funds tracked by Wall St. Rank hold CALA as of Q2 2018.

  • Allianz Asset Management reported no remaining Calithera Biosciences, Inc position as of Q2 2018 after selling out during the quarter.
  • Allianz Asset Management sold 4,098 Calithera Biosciences, Inc shares in Q2 2018, an estimated $516K.
  • Allianz Asset Management first reported a position in Calithera Biosciences, Inc in Q4 2017 and held it in 2 quarters.
  • Allianz Asset Management's Calithera Biosciences, Inc position peaked at $665K in Q4 2017.
  • 90 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2018.

Based on Allianz Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.